Aurinia Pharmaceuticals Inc (AUPH)

[Jesspro]

Ah, we’ve been together through thick and thin and this one is no different, BR. In the end, we always shake our hand. As the Beatles said, “it won’t be long, yeah”.

[biotech_researcher]

Jess, I would personally defend it at $3 so it would not get to that number..

[rosemountbomber]

No question the baby is getting thrown out with the bathwater in the case of Auphie, since they are in a good cash position and are actually earning a lot more interest than they are paying, by far. But Universe forbid that this strategic reviews comes up empty for a buyer.

[Ganz]

Cerv, sounds like you’d rather be right than make a profit, so you can yell at your brother every thanksgiving?
Listen, Q3 results come out for AUPH in a little over a month from now.Bio’s selling for under 20 bucks a share and making profit are few and far between.Most big Pharma companies are needing to keep the pipeline going and AUPH sales are up exponentially every quarter.I don’t understand what your afraid of dude,I think you just need a hug and I’m volunteering Biotech researcher for the task……I”ll bet he may even throw in a reach around.

[Zeppo]

For sure.........industry wide, however, institutions look at burn rates, delays in test results, and the prospect of higher borrowing costs. Companies with decent balance sheets get caught up in a "guilt by association" scenario when times are tough for the industry.

[zzaatt]

That may well be true in general, but given that Aurinia has no debt and enough cash reserves to go for years, discerning investors and potential buyer should not be deterred. I assume that any interested BP has plenty of cash to make the deal.

[Zeppo]

Lengthy interest rate hikes always take their toll on biotech.

[cervelo]

based on what?
all we have is a declining stock price and a do nothing ceo

deal with the facts and not sky high wishes

[Ganz]

Great posts Jess, we’re so close to AUPH just blowing up

[Jesspro]

There’s nowhere to go but up unless it wants to revisit your fav number.

[biotech_researcher]

“I have bad news for you: it WILL go up!”

How do you know? The market is going through some indigestion right now.

[zzaatt]

I guess the market didn't think much of the new bod member

Too early to tell!
The PPS of the company on any given day moves based on a multitude of variables, not least of which is the market at large.
I don't know how "newbie" feels today, but you seem to go into a spasm of masochistic pleasure on "bad news" no matter how transient.
I have bad news for you: it WILL go up!

[cervelo]

newbie must be ecstatic today.
nothing like losing money and shareholder value to put a smile on his face.
thank you petie
I guess the market didn't think much of the new bod member, when actually bringing him on board should have been a positive.

[biotech_researcher]

Not sure:

https://stocktwits.com/Big_Red2/message/545681979

[Jesspro]

The kind of things that big pharma can do to an upcoming drug like Lupkynis. The potential is staggering. If cyclosporine is in the mix of many immunosuppressive conditions, how much more if Lupy gets recognition, a safer and better alternative.

https://www.drugs.com/drug-class/calcineurin-inhibitors.html

[Jesspro]

Maybe this(link below) is one of the reasons why PG is hesitant in selling Auph or selling it cheap. It has so much potential. In the link, cyclosporin and Voclosporin were used in the trial for ulcerative colitis yielding similar results but Voclosporin has a better safety profile than cyclosporine. On the other hand, use of cyclosporine A is hampered by significant toxicities including nephrotoxicity, hypertension, dyslipidemia and hyperuricemia. It’s all in the link.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289195/

[moosedogger]

........just my two cents.

No way those thoughts are only worth 2 cents! Not even factoring in these inflationary times, I say they're very possibly gold, and at the least worth a few $G's.

Thanks and cheers!

[Jesspro]

In my opinion, If only we have unlimited developmental funding like big pharma, this drug will be a novel drug in many immunosuppressive conditions, one in particular is the cytokine storm attacking covid patients during the pandemic when the immune systems of covid patients were in overdrive, the others are conditions treated by cyclosporine. It will go a long way if it is in big pharma’s hand or if we are partnered with them, just my two cents.

[moosedogger]

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289195/

[moosedogger]

A new drug for over 6,500 patients with lupus nephritis in Italy - Healthcare

https://newsrnd.com/life/2023-09-21-a-new-drug-for-over-6-500-patients-with-lupus-nephritis-in-italy---healthcare.SyGxdoDFyp.html

[moosedogger]

Tony seems confident..........

$AUPH
Dear Fellow Shareholders,
this development garanties maximization of shareholders value.
Best,
Tony pic.twitter.com/pdBGDUtlpv

— Tony K (@TonKhalife) September 21, 2023

[rosemountbomber]

Thanks for posting. Hope they are genuine about feeling confident:

“We are confident that meaningful value creation is on the horizon for Aurinia shareholders now that the Board has initiated a strategic review and made significant governance enhancements, including by replacing its Chair and appointing new directors to the Board.”

[thesaud]

https://finance.yahoo.com/news/aurinia-board-directors-appoints-dr-100000228.html

[Ganz]

Also, today…
MIRM gets 70 PT

[Ganz]

Ha!

[biotech_researcher]

Jeepers….

[Jesspro]

Especially days like today, you’re like Nostradamus, Newbie, predicting the manifestation of a rant hours in advance. I get more than a giggle. It’s like a hemorrhoid reacting to a spicy food once it passes the mouth. Sorry, he’ll be here ranting and raving till they closed the shop.

[cervelo]

then you have had more excitement than moist have lately.
fact. we are down 4.00 dollars since petie said he was focusing on shareholder value, quick someone get the man some glasses.
I am so happy fo you newbie that you find pleasure in a continued declining share price.

[Newbie1421]

Sometimes I get a little excited when I see AUPH have a tough day. I know that we are going to get a Cervelo lunatic rant and that makes me giggle every time.

[biotech_researcher]

That is it. I’m on the hotline to Glickman on Monday…..

[Whalatane]

Kiwi's wife would tell you that Lupy is finding use as a " last resort " drug ...when the patients eGFR is below 25 and still declining . Dialysis usually starts around a eGFR of 15 . eGFR is a kidney function test.
So it's an expensive niche drug .....but a very important drug for those that need it.

She's more interested in ARDX's drug for controlling serum phosphate ...Xphozah ...since most of her patients can not control their phosphate levels with the current binders .
Japan PDUFA for Xphozah this month and the US PDUFA by Oct 17th /23

Do your own DD ...above is info , not investment advice
Kiwi

[Jesspro]

Looks better than Auph at this point.

[Jesspro]

Kiwi’s wife calls that brain hypoxia

[Ganz]

It’s just getting warmed up, it’s just like AUPH

[moosedogger]

Maybe open a window in your clown car- you're not getting enough oxygen to your brain

Sorry you bought at the top amidst the hysteria; that has to be painful

[rosemountbomber]

The IRS uses the purchase and sale dates. Boggle away.

[moosedogger]

RMB .............arbitrary starting point...........

Arbitrary? Hardly! The IRS doesn't see it that way. You really don't use YTD as a benchmark? Wowser!

The mind boggles!

[Jesspro]

No Ganz. It was already high by the time I had the liquidity. Yeah, I know I missed it.

[Ganz]

Jess, did you ever get in on Mirm?

[rosemountbomber]

What a way to pick an arbitrary starting point. How about comparing to Oct 25, 2021.

[moosedogger]

bikeman- AUPH YTD chart says $5.64 in January

and $9.12 today. Not bad so far

[cervelo]

I would say the stock chart and continued falling share price should be a concern

[Jesspro]

https://finance.yahoo.com/news/heres-why-were-not-concerned-112731307.html

[moosedogger]

Cosa, I get it. I don't have a problem with it; noted only for accuracy

cheers

[Jesspro]

Yeah, I forgot someone posted that it was a mandated sale for tax purposes. So he’s still a Virgin on this matter, although one could infer that a sale is a sale.

[rosemountbomber]

Yep. Although MKT Capital recommended withholding for PG, but Iljin still voted for PG. If they flip, its all over.

Looks like the early results of the examination of my head is seemingly positive. Picked up more shares at $9 and in three trading sessions since it has been up, up, and up. If I could only be so lucky every time I make a purchase! LOL

[Cosa]

The only stall tactic I can see is replacing those board members with his buddies. Not sure if only the board can fire the CEO? Depends how bylaws are written. But if you look back at the votes from AGM, it will not take much more to get any board member removed. A 7 million swing can pretty much remove anyone. Shareholders are extremely strong together.

For Withheld Broker non votes
Dr. George Milne 33,353,826 36,937,244 20,017,735
Mr. Peter Greenleaf 42,236,274 28,054,796 20,017,735
Dr. David R.W. Jayne 43,010,758 27,280,312 20,017,735
Mr. Joseph P. Hagan 33,521,086 36,769,984 20,017,735
Dr. Daniel Billen 43,311,724 26,979,346 20,017,735
Mr. R. Hector MacKay 40,459,283 29,831,787 20,017,735
Ms. Jill Leversage 43,920,170 26,370,900 20,017,735
Dr. Brinda Balakrishnan 43,997,296 26,293,774 20,017,735

[Cosa]

32,750 was for taxes, line 5. This is from form 4 filed on 3/2/2023 for PG.

1. Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date.
2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
3. Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,221 shares of common stock were acquired on May 31, 2022 and 1,883 shares of common stock were acquired on November 30, 2022.
4. The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 667,407 newly awarded RSUs, 312,240 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 32,967 shares of common stock. On March 2, 2023, 104,080 of Prior RSUs vested and 208,160 of Prior RSUs remained unvested.
5. Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs.

[Jesspro]

Ah, didn’t know about that, sleeping on the job eh.

[moosedogger]

He also hasn’t sold a single share ever far as I know.

This source says in the last 12 months there has been 1 insider buy and 5 insider sells (including PG who sold 32,750 @ $8.94)

https://www.marketbeat.com/stocks/NASDAQ/AUPH/insider-trades/

3/2/2023 Peter Greenleaf CEO Sell 32,750 $8.94 $292,785.00